International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 58-62 www.ijprajournal.com ISSN: 2456-4494

Impact and Contribution of Ai in Transforming Pharmacological Research

Shaik Nabi Rasool[1*], Anjan D[2], Abubakar[3], Atem Edward[4], Muzzammil[5]

1- Assistant Professor, Department of Pharmaceutical Analysis, Acharya & BM Reddy College of Pharmacy, Bengaluru, INDIA.*

2 - Assistant Professor, Department of Pharmaceutical Chemistry, Acharya & BM Reddy College of Pharmacy, Bengaluru, INDIA.

3 - Student of Pharmacy, Department of Pharmacology, Acharya & BM Reddy College of Pharmacy, Bengaluru, INDIA

4 -Student of Pharmacy, Department of Pharmacology, ABMRCP, Bengaluru, INDIA

5 -Student of Pharmacy, Department of Pharmacology, ABMRCP, Bengaluru, INDIA

Date of Submission: 01-11-2025 Date of Acceptance: 10-11-2025

ABSTRACT

Artificial intelligence (AI) is transforming healthcare and pharmaceutical sciences by enabling data-driven decision-making, early disease detection, and process automation. In pharmacology, AI integrates computational models and machine learning (ML) to accelerate drug discovery, optimize development pipelines, and improve patient outcomes. This review outlines the impact of AI across key domains, including drug discovery and design, target identification, drug repurposing, preclinical and clinical trial optimization, and pharmacovigilance. By leveraging genomics, proteomics, and real-world data, AI enhances efficiency, reduces costs, and supports the advancement of personalized medicine. Despite these advances, challenges such as regulatory uncertainty, data quality issues, algorithmic bias, and ethical concerns regarding privacy and transparency remain. Realizing the full potential of AI requires harmonized regulations, ethical governance, robust datasets, and interdisciplinary collaboration. With responsible integration, AI holds the potential to revolutionize pharmacological research and global patient care.

Keywords: Artificial Intelligence, Machine Learning, Pharmacology, Drug Discovery, Drug Repurposing, Preclinical Trials, Clinical Trials, Pharmacovigilance, Personalized Medicine

I. INTRODUCTION

Artificial intelligence (AI) is the simulation of human cognitive functions such as learning, reasoning, and problem-solving through computational models, algorithms, and rule-based systems. In healthcare, AI is rapidly advancing, influencing clinical decision-making, disease diagnostics, automation, and research by analyzing vast amounts of data. Its key technologies include machine learning (ML), natural language processing, robotics, and process automation, with ML particularly effective in early disease detection[1]. AI has been transforming pharmaceutical research by accelerating drug discovery, formulation, and testing through analysis of large biological data sets like genomics and proteomics. ML enhances efficiency by predicting pharmacokinetics, toxicity, and optimizing lead compounds, thereby reducing costs and reliance on animal testing. AI also supports personalized medicine, process optimization, and improved treatment outcomes, offering promising advancements in drug development and patient care[2]. AI has become a transformative force in healthcare and pharmaceutical sciences by mimicking human cognitive functions such as learning, reasoning, and decision-making [3]. In medicine, AI technologies like machine learning (ML), natural language processing (NLP), and robotics are applied in clinical decision-making, imaging, diagnosis, and patient care, offering more accurate and efficient outcomes [4]. In pharmaceuticals, AI accelerates drug discovery and development by analyzing and identifying novel therapeutic targets and predict drug–disease interactions [5]. Machine learning algorithms also predict pharmacokinetics, toxicity, and optimize lead compounds, reducing costs and minimizing animal testing [6].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 58-62 www.ijprajournal.com ISSN: 2456-4494

II. KEY AREAS OF TRANSFORMING PHARMACOLOGICAL RESEARCH

2.1. Discovery and design

Artificial Intelligence (AI) has revolutionized early-stage drug discovery through structure-based screening, QSAR modeling, and bioactivity prediction. Zhavoronkov et al. developed a generative model (GENTRL) that identified DDR1 kinase inhibitors within just 21 days, demonstrating faster and more efficient drug lead identification than traditional approaches [7]. Machine learning (ML) supports virtual screening, molecular docking, and activity prediction by learning structure-activity relationships from vast chemical libraries [8]. This has reduced dependency on wet-lab testing while enhancing hit-to-lead transition speed. Such methods also support de novo molecular design by discovering novel scaffolds (5). AI is revolutionizing drug discovery by predicting PK/PD profiles, ADME properties, and toxicities, thereby reducing late-stage failures and development costs. It also enables drug repurposing through integrated clinical and molecular data, advancing precision-driven and cost-effective therapeutics [9].

2.2. TARGET IDENTIFICATION

Following the initial stage of drug discovery, where AI assists in identifying potential lead compounds and scaffolds, the next crucial step is determining the precise biological targets these molecules act upon. Without accurate target identification, even promising candidates may fail in later stages due to lack of specificity or unforeseen side effects. Thus, AI-driven methods seamlessly extend from discovery into the validation of molecular targets, ensuring that compounds are paired with the right receptors, enzymes, or proteins.

AI-driven platforms enable rapid and accurate identification of therapeutic targets by integrating omics and clinical datasets. Paul et al. highlighted the use of deep learning and reinforcement learning for elucidating drug-target interactions and optimizing lead candidates (8). ML clustering methods assist in discovering disease-specific targets and biomarkers. Furthermore, predictive modeling enables the identification of compounds with selectivity toward novel proteins or receptors. AI algorithms also help narrow down viable targets early, reducing cost and attrition later in the development pipeline [5]. AI accelerates drug target prediction by integrating genomics, proteomics, and clinical data with ML/DL models to uncover novel therapeutic candidates. Techniques like SVMs, random forests, CNNs, and RNNs enable precise biomarker discovery, disease subtype classification, and identification of targets such as SARS-CoV-2 Mpro and hERG [10].

2.3. DRUG REPURPOSING

Once therapeutic targets are identified and validated, AI can extend its application toward finding new purposes for already existing drugs. This continuation is especially important because linking compounds with established safety profiles to novel targets can save years of development time and massive costs. Thus, drug repurposing acts as a logical progression from discovery and target identification, where AI leverages known drugs to address new or urgent diseases.

AI has shown significant success in repurposing existing drugs, particularly in response to urgent medical crises like the COVID-19 pandemic. Jin et al. applied deep learning to identify synergistic drug combinations, such as remdesivir with reserpine and IQ-1S, demonstrating effective antiviral activity in vitro (11). Stokes et al. used neural networks to discover Halicin, a novel antibiotic with activity against resistant pathogens, showcasing the model's ability to uncover structurally unique drug candidates (12). Additionally, Wang et al. surveyed AI platforms like BenevolentAI and DeepMind, which supported rapid COVID-19 therapeutic identification (13).

2.4. PRECLINICAL TRIALS

After drug repurposing or the development of novel candidates, the process naturally moves into preclinical evaluation to test safety and efficacy in controlled environments. Here, AI not only continues its role from earlier stages but also expands to designing studies, predicting outcomes, and validating biomarkers. By bridging the gap between laboratory findings and clinical translation, AI ensures that only the most promising candidates proceed to human trials.

AI applications in preclinical development enhance trial design, endpoint prediction, and biomarker validation. Ku et al. reviewed how natural language processing (NLP) improves protocol matching and patient recruitment, while ML enables adaptive trial structures and real-time outcome prediction (14). In oncology, Fountzilas et al. used ML to stratify patients based on biomarker and omics profiles, improving treatment responses and trial efficiency (15). For toxicity prediction, Xu et al. developed a deep learning model for drug-induced liver injury (DILI), achieving high

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 58-62 www.ijprajournal.com ISSN: 2456-4494

sensitivity and outperforming traditional QSAR methods (16). AI is revolutionizing clinical trials by improving patient recruitment, real-time monitoring, and structured data extraction, while NLP aids in processing unstructured EHR data despite challenges. Emerging tools like digital twins and AI-driven imaging analysis further enhance personalized medicine and real-world clinical research [9].

2.5. CLINICAL TRIAL DESIGN AND MANAGEMENT

Once preclinical evaluations establish a candidate's potential, the next transition is into human-based testing. Clinical trials represent the pivotal phase where AI shifts from laboratory predictions to directly influencing patient care. During the preclinical stage, AI is mainly applied for predictive modeling to assess safety and efficacy, guiding early decision-making.[17] In contrast, its role in clinical research is broader—refining trial protocols, enabling adaptive designs, and supporting real-time monitoring of treatment responses. Importantly, regulatory agencies are recognizing AI's role: the U.S. FDA (2025) proposed a draft guidance on using AI for regulatory decision-making, while the EMA (2024) issued a reflection paper emphasizing adherence to Good Clinical Practice (GCP). These evolving perspectives highlight that AI-driven clinical trial management not only improves efficiency but also ensures alignment with safety, ethics, and regulatory compliance—positioning AI as a distinct contributor to modern drug development.[18]

2.6. PHARMACOVIGILANCE

The logical continuation after clinical trials is the long-term monitoring of drugs once they reach the market. Even with rigorous discovery, preclinical testing, and clinical trials, unforeseen adverse effects can emerge when drugs are used in diverse populations. Here, AI extends its contribution into pharmacovigilance, ensuring continuous safety surveillance and improving post-marketing outcomes.

AI enhances pharmacovigilance by mining real-world data from electronic health records (EHRs), social media, and spontaneous reporting systems. Kompa et al. reviewed machine learning techniques for adverse event detection, highlighting how NLP and supervised learning uncover hidden drug-event relationships in unstructured data (19). AI enables more proactive and real-time monitoring of drug safety, essential for improving post-market surveillance. Despite its promise, underreporting and inconsistent data formats remain barriers to reliability and scalability.



Fig 1:Key areas of transforming pharmacological research

III. CHALLENGES OF AI IN PHARMACEUTICAL RESEARCH

AI integration in drug development faces key challenges as highlighted below:

Data quality and availability

A major challenge in AI-based drug discovery is the lack of high-quality annotated datasets for training. The mixture of data from sources like chemical structures, assays, and clinical trials complicates integration and standardization. Concrete data curation, preprocessing, and bias-mitigation techniques are essential. These steps ensure that AI models produce reliable, equitable outcomes across diverse patient populations [10].

Ethical concerns,

The "black box" nature of deep learning raises concerns over interpretability in high-stakes decisions. Ethical concerns, including algorithmic bias and patient privacy, require multi-stakeholder collaboration to develop trustworthy, transparent AI ecosystems (8).The integration of AI into pharmacy practice raises key ethical concerns, including data security, job loss, and insufficient regulation.

Tech literacy plays a vital role in fostering ethical awareness, highlighting the need for targeted education and governance.To ensure responsible AI use, clear legal frameworks must balance

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 58-62 www.ijprajournal.com ISSN: 2456-4494

innovation with patient rights and transparency in decision-making[10].

AI and ML in pharmaceutical research face critical ethical challenges around data privacy, algorithmic bias, and transparency.Ethical safeguards like informed consent, anonymization, and responsible data handling are essential to protect patient information.Promoting transparent and interpretable algorithms enhances trust and helps correct biased outcomes in healthcare systems[20].

Product Liability

When AI used in drug discovery, clinical trials, or healthcare causes harm, it is often unclear whether responsibility lies with developers, pharmaceutical companies, or clinicians. [21]This uncertainty creates barriers to adoption, as courts apply inconsistent standards and patients may redirect claims. Establishing clear liability models and risk-mitigation strategies is essential to ensure safety and build trust.[22]

Regulatory barriers,

Regulatory bodies have yet to establish comprehensive validation and approval frameworks for AI-driven tools. Variability in data quality and formatting hampers reproducibility and scalability of ML models (5).

Future Aspects

Addressing the challenges of AI in pharmaceutical research requires a multipronged approach. The development of large, high-quality, and standardized multi-institutional datasets, combined with advanced preprocessing and bias-mitigation strategies, will be essential to improve reliability and inclusivity. Ethical safeguards such as informed consent, anonymization, and interpretable algorithms must be strengthened to protect patient privacy and enhance trust. Equally important are clear liability frameworks to define accountability in cases of AI-related harm, alongside harmonized regulatory standards capable of validating adaptive software tools and ensuring reproducibility.

Beyond overcoming these barriers, AI holds transformative potential for personalized pharmacology. Sartori et al. demonstrated how deep learning can integrate genomic, transcriptomic, and proteomic data to identify prognostic biomarkers across diseases such as cancer and neurodegeneration (23). Similarly, Chiu et al. and Xia et al. developed multimodal models that combine genomic profiles with drug properties, enabling the prediction of drug responses across cell lines and the discovery of novel gene–drug associations (24,25). Embedding such models within clinical workflows could provide dynamic feedback, optimize therapeutic decision-making, and accelerate the implementation of precision medicine.

Fig 2: Challenges of AI in pharmaceutical research

IV. CONCLUSION

AI is reshaping pharmacological research across the entire drug development pipeline—from discovery and target identification to clinical trials and post-marketing surveillance. By enhancing efficiency, reducing attrition, and enabling novel therapeutic insights, AI offers a powerful means of accelerating innovation. However, its widespread integration is contingent on addressing persistent challenges related to data quality, ethical safeguards, liability, and regulatory oversight. Future progress will depend on building robust datasets, ensuring transparency, and establishing harmonized governance frameworks. With these foundations, AI can fully realize its potential in driving personalized pharmacology, supporting precision medicine, and ultimately improving patient outcomes.

REFERENCES

[1]. Bhattamisra SK, Banerjee P, Gupta P, Mayuren J, Patra S, Candasamy M. Artificial Intelligence in Pharmaceutical and Healthcare Research. Big Data and Cognitive Computing. 2023 Jan 11;7(1):10.

[2]. Vora LK, Gholap AD, Jetha K, Thakur RRS, Solanki HK, Chavda VP. Artificial

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 6 Nov - Dec 2025, pp: 58-62 www.ijprajournal.com ISSN: 2456-4494

Intelligence in Pharmaceutical Technology and Drug Delivery Design. Pharmaceutics. 2023;15(7):1916–6.
[3]. Jiang F, Jiang Y, Zhi H, et al. Artificial intelligence in healthcare: past, present and future. Stroke Vasc Neurol. 2017;2(4):230–243.
[4]. Esteva A, Robicquet A, Ramsundar B, et al. A guide to deep learning in healthcare. Nat Med. 2019;25:24–29.
[5]. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18:463–477.
[6]. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discov Today. 2019;24(3):773–780.
[7]. Zhavoronkov A, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019.
[8]. Paul D, et al. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021.
[9]. van der Lee M, Swen JJ. Artificial intelligence in pharmacology research and practice. Clinical and Translational Science. 2022 Oct 17;16(1):31–6.
[10]. Kant S, Deepika, Roy S. Artificial intelligence in drug discovery and development: transforming challenges into opportunities. Discover Pharmaceutical Sciences. 2025 Jun 2;1(1).
[11]. Jin W, et al. Predicting drug synergy for COVID-19 using deep learning. Proc Natl Acad Sci USA. 2021;118(30):210
[12]. Stokes JM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.
[13]. Wang LL, et al. AI for COVID-19 drug repurposing. Brief Bioinform. 2021;22(2):726–741.
[14]. Ku JP, et al. AI in clinical trials: design and execution. NPJ Digit Med. 2021;4:97.
[15]. Fountzilas E, et al. AI-enabled patient stratification improves trial outcomes. NPJ Digit Med. 2025.
[16]. Xu Y, et al. Deep learning for predicting drug-induced liver injury. J Chem Inf Model. 2015;55(10):2085–2093.
[17]. Wimalawansa SJ. Reforming Food, Drug, and Nutraceutical Regulations to Improve Public Health and Reduce Healthcare Costs. Foods. 2025 Jun30;14(13):2328.
[18]. Alexander M, Solomon B, Ball DW, Sheerin M, Dankwa-Mullan I, Preininger AM, et al. Evaluation of an artificial intelligence clinical trial matching system in Australian lung cancer patients. JAMIA Open. 2020 Jul 1;3(2):209–15.
[19]. Kompa B, et al. Machine learning for pharmacovigilance: a review. Drug Saf. 2022;45(5):509–522.
[20]. Kandhare P, Kurlekar M, Deshpande T, Pawar A. A review on revolutionizing healthcare technologies with AI and ML applications in pharmaceutical sciences. Drugs and Drug Candidates. 2025 Mar 4;4(1):9.
[21]. Chagal-Feferkorn KA. Am I an algorithm or a product: when products liability should apply to algorithmic decision-makers. Stan. L. &Pol'yRev..2019;30:61.
[22]. Maliha G, Gerke S, Cohen IG, Parikh RB. Artificial intelligence and liability in medicine: balancing safety and innovation. The Milbank Quarterly. 2021 Apr 6;99(3):629.
[23]. Sartori F, Codicè F, Caranzano I, Rollo C, Birolo G, Fariselli P, Pancotti C. A Comprehensive Review of Deep Learning Applications with Multi-Omics Data in Cancer Research. Genes. 2025 May 28;16(6):648.
[24]. Chiu YC, Chen HI, Zhang T, Zhang S, Gorthi A, Wang LJ, Huang Y, Chen Y. Predicting drug response of tumors from integrated genomic profiles by deep neural networks. BMC medical genomics. 2019 Jan 31;12(Suppl 1):18.
[25]. Feng F, Shen B, Mou X, Li Y, Li H. Large-scale pharmacogenomic studies and drug response prediction for personalized cancer medicine. Journal of Genetics and Genomics. 2021 Jul 20;48(7):540-51.